We hereby inform you that the management of the company met with group of investor held by the Hem Securities Samrudhi 2025- Virtual SME Conclave through virtual mode on Thursday, December 4,2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Asarfi Hospital's management met investors at a virtual SME conclave on December 4, 2025, sharing its H1 FY26 results and strategic roadmap. Revenue grew 50% year-on-year to ₹80.6 crore, EBITDA rose 38% to ₹15.86 crore (20% margin), and profit after tax jumped 70% to ₹7.32 crore. Inpatient volumes more than doubled to 12,361 patients. The company outlined its 'Vision 2027' plan targeting 500 beds, ₹200 crore in revenue, EBITDA margins of 25–27%, and PAT margins of 13–15%, supported by expansion into Bihar and Eastern UP, a Bone Marrow Transplant unit, a Multi Organ Transplant facility via Gleneagles MoU, and a new education vertical. The filing notes that no unpublished price-sensitive information was disclosed.
Strong H1 FY26 numbers and clear multi-year growth targets should be viewed positively by retail investors, though the company's expansion plans in newer geographies and verticals (education) carry execution risk. The stock may see short-term interest from the SME investor community following this engagement.